Neoadjuvant Sorafenib Treatment of Clear Cell Renal Cell Carcinoma and Release of Circulating Tumor Fragments

Neoadjuvant Sorafenib Treatment of Clear Cell Renal Cell Carcinoma and Release of Circulating Tumor Fragments

BACKGROUND: Clear cell renal cell carcinoma (ccRCC) is characterized by high constitutive vascular endothelial growth factor A (VEGF-A) production that induces a specific vascular phenotype. We previously reported that this phenotype may allow shedding of multicellular tumor fragments into the circ...

Full description

Bibliographic Details
Main Authors: Gursah Kats-Ugurlu, Egbert Oosterwijk, Stijn Muselaers, Jeannette Oosterwijk-Wakka, Christina Hulsbergen-van de Kaa, Mirjam de Weijert, Han van Krieken, Ingrid Desar, Carla van Herpen, Cathy Maass, Rob de Waal, Peter Mulders, William Leenders
Format: Article
Language:English
Published: Elsevier 2014-03-01
Series:Neoplasia: An International Journal for Oncology Research
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558614000189

Internet

http://www.sciencedirect.com/science/article/pii/S1476558614000189

Similar Items